Oral mikronize progesteronun ilk trimester tarama belirteçlerine ve yeni doğan sonuçlarına etkisi
Amaç: ilk trimester gebeliklerde kullanılan oral mikronize progesteronun (OMP), ilk trimester tarama belirteçleri olan; ense saydamlığı kalınlığı, anne serum beta-insan koryonik gonadotropin (β-hCG) ve gebelikle ilişkili plazma protein-A (PAPP-A) düzeylerine etki edip etmediğinin araştırılması amaçlandı. Ayrıca, OMP kullanan gebe kadınlarda yenidoğan sonuçlarını değerlendirmeyi amaçladık. Yöntemler: Bu çalışma Ocak 2015-Ağustos 2017 tarihleri arasında 1192 gebe kadın dahil olmak üzere retrospektif olarak yapıldı. Vücut kitle indeksi (VKİ), maternal ve gestasyonel yaş, anne serum PAPP-A ve serbest β-hCG düzeyleri, ense saydamlığı ve ölçümü baş-popo uzunluğu (CRL) ölçümü, fetal cinsiyet, fetal doğum ağırlığı, Apgar skoru 5.dakika
The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome
Objective: It was aimed to investigate whether or not nuchal translucency(NT) thickness, maternal serum free betahuman chorionic gonadotropin(β-hCG) and pregnancy-associated plasma protein-A(PAPP-A) levels may affected bythe use of oral micronized progesterone(OMP) in first trimester pregnancies. Also we aimed to evaluate pregnancyoutcome in pregnant women using OMP.Method: This study was performed retrospectively including 1192 pregnant women, between January 2015 andAugust 2017. Body mass index(BMI), maternal and gestational age, levels of maternal serum PAPP-A and free β-hCG,NT measurement and the crown–rump length(CRL), fetal sex, fetal birth weight, Apgar score 5thminute
___
- 1. Alldred SK, Takwoingi Y, Guo B, et all. First trimester
ultrasound tests alone or in combination with first
trimester serum tests for Down's syndrome screening.
Cochrane Database of Systematic Reviews 2017: 3.
- 2. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon
O. Multicenter study of first-trimester screening for
trisomy 21 in 75821 pregnancies: results and
estimation of the potential impact of individual riskorientated two-stage first-trimester screening.
Ultrasound Obstet Gynecol. 2005; 25: 221–6.
- 3. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides
KH. First-trimester screening for trisomy 21 in
singleton pregnancies achieved by assisted
reproduction. Hum Reprod. 2001; 16: 501–1504.
- 4. Walch KT, Huber JC. Progesterone for recurrent
miscarriage: truth and deceptions. Best Pract Res Clin
Obstet Gynaecol. 2008; 22: 375-89.
- 5. Sotiriadis A, Papatheodorou S, Makrydimas G.
Threatened miscarriage: evaluation and management.
Brid Med J. 2004; 329: 152.
- 6. Czajkowski K, Sienko J, Mogilinski M, et all.
Uteroplacental circulation in early pregnancy
complicated by threatened abortion supplemented
with vaginal micronized progesterone or oral
dydrogesterone. Fertil Steril. 2007; 87: 613.
- 7. Weiss JL, Malone FD, Vidaver J, et al. Threatened
abortion: a risk factor for poor pregnancy outcome, a
population-based screening study. Am J Obstet Gynecol
2004; 190: 745.
- 8. Alp M, Diclehan O. Tekrarlayan spontan abortusları
olan çiftlerde genetik araştırmalar. Dicle Tıp Derg.
2006; 33: 71-80.
- 9. Dunn CL, Kelly RW, Critchley HO. Decidualization of
the human endometrial stromal cell: an enigmatic
transformation. Reprod Biomed Online. 2003;7: 151.
- 10. Turgal M, Aydin E, Ozyuncu O. Effect of micronized
progesterone on fetal‐placental volume in
first‐trimester threatened abortion. J Clin Ultrasound.
2017; 45: 14-9.
- 11. Wang J, Liu S, Qin HM, Zhao Y, Wang XQ, and Yan Q.
Pregnancy-associated plasma protein A up-regulated
by progesterone promotes adhesion and proliferation
of trophoblastic cells. Int J Clin Exp path. 2014; 7: 1427-
37.
- 12. Giorlandino C, Cignini P, Padula F, et all. Effects of
exogenous progesterone on fetal nuchal translucency:
an observational prospective study. Am J Obstet
Gynecol. 2015; 212: 335-e1.
- 13. Keçecioğlu M, Tokmak A, Keçecioğlu TS, et all. Does
progesterone therapy increase nuchal translucency in
women with threatened miscarriage? Ginekol pol.
2016; 87: 390-4.
- 14. Kalem MN, Kalem Z, Bakırarar B, Ergün A, Gürgan T.
The effect of progesterone use in the first trimester on
fetal nuchal translucency. J Turk Ger Gynecol Assoc.
2018; 19: 29.